Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 4342.

https://doi.org/10.1182/blood-2019-129680

Published: 2019

Journal Articles

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Masaaki Hotta, MD, Satake Atsushi, MD PhD, Yukie Tsubokura, MD, Yoshiko Azuma, MD, Hideaki Yoshimura, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 5672.

https://doi.org/10.1182/blood-2019-129959

Published: 2019

Journal Articles

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Aya Nakaya, MD PhD, Shinya Fujita, MD PhD, Atsushi Satake, MD PhD, Takahisa Nakanishi, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Ryo Saito, MD, Akiko Konishi, MD, Masaaki Hotta, MD, Hideaki Yoshimura, MD, Kazuyoshi Ishii, MD MPH, PhD, Tomoki Ito, MD PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2018-99-117823

Published: 2018

Journal Articles

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2018-99-113282

Published: 2018

Journal Articles

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Tomoki Ito, MD PhD, Kayoko Kibata, MD, Muneo Inaba, PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 1007.

https://doi.org/10.1182/blood.V130.Suppl_1.1007.1007

Published: 2017

Journal Articles

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Atsushi Satake, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 4092.

https://doi.org/10.1182/blood.V130.Suppl_1.4092.4092

Published: 2017

NARROW

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only